Despite numerous setbacks, efforts to attack GBM via EGFR targeting persist with the third-generation irreversible inhibitor AZD9291 (Osimertinib) that presents excellent blood–brain barrier penetration and promising efficacy in preclinical tests [265]. The gene discussed is EGFR; the disease is glioblastoma.